- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06474182
Sammenligning af virkningerne af apixaban på thrombingenerering hos patienter med de Novo multipelt myelom (ProApix)
Sammenligning af virkningerne af profylaktisk administration af apixaban på trombingenerering hos patienter med de Novo multipelt myelom og patienter, der gennemgår en operation for total knæudskiftning
Patients with multiple myeloma (MM) are at high risk of venous thromboembolism (VTE) and these patients require adequate thromboprophylaxis. Following the publication of the AVERT clinical study, Apixaban is strongly recommended as a prophylactic treatment option for patients with cancer, based on high quality of evidence and a favorable efficacy/safety profile. A multicenter and ancillary study - APIXABOR - that measured the plasmatic concentration of Apixaban in patients with MM and treated with preventive dose has been conducted. The peak drug concentration was superior in MM plasma, as compared to non-myeloma patients under prophylaxis. Therefore, the present study evaluated whether differences in pharmacokinetics have an impact on pharmacodynamics (i.e. decrease in coagulability in MM patients as compared to non-MM patients undergoing a surgery for total knee replacement who also have VTE prophylaxis). In fine, this study may inform to better manage thromboprophylaxis in MM patients.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Emilie CHALAYER, MD
- Telefonnummer: 33 (0)477822814
- E-mail: emilie.chalayer@chu-st-etienne.fr
Undersøgelse Kontakt Backup
- Navn: Florence RANCON
- Telefonnummer: 33 (0)4 77 82 94 58
- E-mail: florence.rancon@chu-st-etienne.fr
Studiesteder
-
-
-
Saint-Etienne, Frankrig, 42055
- Rekruttering
- CHU de Saint-Etienne
-
Underforsker:
- Julien LANOISELEE, MD
-
Underforsker:
- Ludovic FOUILLET, MD
-
Underforsker:
- Jean-Yves BIEN, MD
-
Underforsker:
- Emmanuelle TAVERNIER, MD
-
Kontakt:
- Emilie CHALAYER, MD
- Telefonnummer: 33 (0)4 77 82 28 14
- E-mail: emilie.chalayer@chu-st-etienne.fr
-
Underforsker:
- Jérôme CORNILLON, MD
-
Underforsker:
- Charlotte DOUBLET, MD
-
Underforsker:
- Tiphany NEEL, MD
-
Underforsker:
- Manon SAPET, MD
-
Underforsker:
- Hugo THEVENET, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years old,
- Signed informed consent,
- Patient covered by a social security scheme.
- Group 1 : patient with a diagnosis of de novo multiple myeloma, with an indication of thromboprophylaxis with Apixaban,
- Group 2 : patient requiring a surgery for total knee replacement, , with an indication of thromboprophylaxis with Apixaban.
Exclusion Criteria:
- Curative doses of anticoagulation treatment,
- Contra-indication to Apixaban,
- Pregnant or breastfeeding woman,
- Refusal to sign consent,
- Patient under legal protection.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Blood sampling of patients with de novo multiple myeloma
Description: Blood sampling of patients with de novo multiple myeloma |
Blood sampling Treatment by Apixaban |
|
Eksperimentel: Blood sampling of patients undergoing total knee replacement
Description: Blood sampling of patients undergoing total knee replacement |
Blood sampling Treatment by Apixaban |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Endogenous Thrombin potential (nM.min)
Tidsramme: 2 hours after Apixaban Treatment
|
Endogenous Thrombin potential (nM.min) as measured with MidiCAT method at the concentration peak 2 hours after 2.5mg Apixaban treatment |
2 hours after Apixaban Treatment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Apixaban concentration (ng/mL)
Tidsramme: Kinetics of 12 hours following Apixaban treatment in both groups
|
Apixaban concentration (ng/mL) as measured by mass spectrometry during 12 hours following Apixaban treatment (2.5mg) in both groups |
Kinetics of 12 hours following Apixaban treatment in both groups
|
|
Pharmacodynamics' kinetics of Endogenous Thrombin Potential
Tidsramme: Kinetics of 12 hours following Apixaban treatment in both groups
|
MidiCAT method measure : Endogenous Thrombin Potential (nM.min) |
Kinetics of 12 hours following Apixaban treatment in both groups
|
|
Pharmacodynamics' kinetics of Lagtime
Tidsramme: Kinetics of 12 hours following Apixaban treatment in both groups
|
MidiCAT method measure : Lagtime (min) |
Kinetics of 12 hours following Apixaban treatment in both groups
|
|
Pharmacodynamics' kinetics of Time to peak
Tidsramme: Kinetics of 12 hours following Apixaban treatment in both groups
|
MidiCAT method measure : Time to peak (min) |
Kinetics of 12 hours following Apixaban treatment in both groups
|
|
Pharmacodynamics' kinetics of Thrombin peak
Tidsramme: Kinetics of 12 hours following Apixaban treatment in both groups
|
MidiCAT method measure : Thrombin peak (M, Thrombin) |
Kinetics of 12 hours following Apixaban treatment in both groups
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Emilie CHALAYER, MD, CHU de Saint-Etienne
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Karsygdomme
- Hjerte-kar-sygdomme
- Neoplasmer
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Hæmatologiske sygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Neoplasmer, Plasmacelle
- Hæmostatiske lidelser
- Paraproteinæmier
- Blodproteinforstyrrelser
- Hæmoragiske lidelser
- Hemiske og lymfatiske sygdomme
- Myelomatose
- Undersøgelsesteknikker
- Håndtering af eksemplar
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Punkteringer
- Kirurgiske procedurer, operative
- Apixaban
- Blodprøveopsamling
Andre undersøgelses-id-numre
- 23CH293
- 2024-515329-27-00 (Ctis)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .